Pts received a median of 2 lines of prior systemic therapy, including anti-PD-(L)1 (78%) and platinum-based chemotherapy (89%); 28% received cetuximab in the RM setting. No cases of interstitial lung disease were reported in this cohort. Conclusions MCLA-129 monotherapy demonstrated antitumor activity in pts with pretreated RM HNSCC with a manageable safety profile.
1 year ago
Clinical
|
MET (MET proto-oncogene, receptor tyrosine kinase)
A phase 1/2 clinical trial of MCLA-129 in solid tumors is ongoing. These data support the further clinical development of MCLA-129 in patients with NSCLC and other solid tumors.
At the data cut-off date of 8 May 2022, 20 pts were enrolled, across the 100, 300, 600, 1000 and 1500 mg cohorts. Median age was 65.5 years (range 43-79). Pts enrolled included: 14 pts with EGFR mutant (mt) NSCLC (4 pts L858R, 8 pts Del19, 1 pt exon 20 insertion , 1 pt with other mutation), 2 pts with c-MET exon 14 mt NSCLC, 1 pt with c-MET amplified gastric adenocarcinoma , 1 pt with squamous esophageal cancer , and 2 pts with HNSCC.
2 years ago
Clinical • P1/2 data
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 20 insertion • MET exon 14 mutation • MET mutation
Mutagenesis analysis identified critical binding residues of domain III of EGFR for MCLA-129 binding that are distinct from cetuximab binding. MCLA-129 is a Biclonics® common light chain bispecific antibody with multiple mechanisms of action including potent inhibition of c-MET and EGFR ligand binding, ligand-induced receptor dimerization and phosphorylation, ADCC and ADCP. MCLA-129 demonstrates significant growth inhibition of a patient-derived EGFR exon20ins tumor in a preclinical xenograft model. A phase 1/2 clinical trial of MCLA-129 in solid tumors is ongoing.
MCLA-129 is glycoengineered to enhance its Fc mediated ADCC and ADCP activity, thus allowing it to inhibit tumor growth independent of EGFR or c-MET signaling. MCLA-129 holds promise as a potential treatment option for NSCLC and other solid tumors.